JP2013510905A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510905A5
JP2013510905A5 JP2012539974A JP2012539974A JP2013510905A5 JP 2013510905 A5 JP2013510905 A5 JP 2013510905A5 JP 2012539974 A JP2012539974 A JP 2012539974A JP 2012539974 A JP2012539974 A JP 2012539974A JP 2013510905 A5 JP2013510905 A5 JP 2013510905A5
Authority
JP
Japan
Prior art keywords
composition
affecting
pta
effective amount
atcc deposit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012539974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510905A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056862 external-priority patent/WO2011060427A2/en
Publication of JP2013510905A publication Critical patent/JP2013510905A/ja
Publication of JP2013510905A5 publication Critical patent/JP2013510905A5/ja
Pending legal-status Critical Current

Links

JP2012539974A 2009-11-16 2010-11-16 サイトカイン及びnf−kbに影響を与える組成物及び方法 Pending JP2013510905A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26163909P 2009-11-16 2009-11-16
US61/261,639 2009-11-16
PCT/US2010/056862 WO2011060427A2 (en) 2009-11-16 2010-11-16 Composition and methods for affecting cytokines and nf-kb

Publications (2)

Publication Number Publication Date
JP2013510905A JP2013510905A (ja) 2013-03-28
JP2013510905A5 true JP2013510905A5 (https=) 2014-01-16

Family

ID=43992472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539974A Pending JP2013510905A (ja) 2009-11-16 2010-11-16 サイトカイン及びnf−kbに影響を与える組成物及び方法

Country Status (6)

Country Link
US (1) US20110117122A1 (https=)
EP (1) EP2501390A4 (https=)
JP (1) JP2013510905A (https=)
BR (1) BR112012011678A2 (https=)
CA (1) CA2780144A1 (https=)
WO (1) WO2011060427A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
EP3258948B1 (en) 2015-02-16 2023-12-06 Zivo Bioscience, Inc. Anti-inflammatory and immunomodulatory compositions comprising klebsormidium and uses thereof
WO2017142906A1 (en) 2016-02-16 2017-08-24 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10480A (en) * 1854-01-31 Improvement in electro-magnettc engines
US15587A (en) * 1856-08-19 Aepabattts for boeing artesian wells
US9479A (en) * 1852-12-21 Improvement in rakes to grain-harvesters
JPS6219528A (ja) * 1985-07-16 1987-01-28 Kurorera Kogyo Kk 制癌剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
EP1212093B1 (en) * 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications
AU7551100A (en) * 1999-09-27 2001-04-30 Algal Ltd. Vegetarian foodstuff
JP2004505925A (ja) * 2000-08-10 2004-02-26 オーシャン、ニュートリッション、カナダ、リミテッド 免疫調節特性を示すクロレラ調製物
US20020119164A1 (en) * 2000-08-18 2002-08-29 Shoji Uchiyama Use of agaricus blazei murill to prevent or treat skin and other disorders
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US20130251698A1 (en) * 2010-10-04 2013-09-26 Health Enhancement Products, Inc. Composition and method for affecting cytokines and nf-kb
US20080031863A1 (en) * 2004-04-23 2008-02-07 Health Enhancement Products, Inc. Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
US7807622B2 (en) * 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US8586053B2 (en) * 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
CA2631773C (en) * 2005-12-02 2022-04-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease

Similar Documents

Publication Publication Date Title
JP2013510905A5 (https=)
Watad et al. Seasonality and autoimmune diseases: the contribution of the four seasons to the mosaic of autoimmunity
Chen et al. Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis
Moschen et al. Interferon-alpha controls IL-17 expression in vitro and in vivo
JP2014530226A5 (https=)
JP2014513088A5 (https=)
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
JP2009520029A5 (https=)
JP2013517784A5 (https=)
WO2011127302A3 (en) Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
EP2853543A8 (en) Anti-blys antibody
FI3250216T3 (fi) Immunomoduloiva koostumus, joka käsittää bifidobakteereja
JP2017519723A5 (https=)
Yu et al. Dysbiosis of gut microbiota induced the disorder of helper T cells in influenza virus-infected mice
PH12021553294A1 (en) Application of progestin in preparation of drug inhibiting cytokine storm
Karo et al. Effects of miana (Coleus scutellariodes (L) Benth) to expression of mRNA IL-37 in Balb/c mice infected Candida albicans
Marlina et al. The effect of miana (coleus scutellariodes [L]) on vascular endothelial growth factor expression in Balb/C mice infected with mycobacterium tuberculosis
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR TREATING PRESENTATIONS
Zhang et al. Effects of sodium tanshinone IIA sulfonate against Marek's disease virus in experimentally infected chickens
IL274974B2 (en) Compositions for prevention or treatment of acute radiation syndrome
MX2020008044A (es) Células asesinas naturales resistentes al factor de crecimiento transformante beta.
WO2013096732A3 (en) Methods of treating or preventing viral diseases by blocking interleukin-21
JP2009518312A5 (https=)
RU2010112734A (ru) Способ элиминации бактерий gardnerella vaginalis и atopobium vaginae при бактериальном вагинозе
Zhang et al. PGBL inhibits the RAW 264.7 cells to express inflammatory factor